Dimensional Fund Advisors LP grew its holdings in RadNet Inc. (NASDAQ:RDNT) by 0.8% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,581,140 shares of the medical research company’s stock after buying an additional 12,736 shares during the period. Dimensional Fund Advisors LP’s holdings in RadNet were worth $16,081,000 as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds and other institutional investors have also modified their holdings of RDNT. FMR LLC raised its position in shares of RadNet by 46.7% in the third quarter. FMR LLC now owns 2,105,744 shares of the medical research company’s stock valued at $31,692,000 after buying an additional 670,255 shares during the last quarter. Phoenician Capital LLC acquired a new stake in shares of RadNet in the fourth quarter valued at about $6,102,000. Global Alpha Capital Management Ltd. acquired a new stake in shares of RadNet in the fourth quarter valued at about $5,594,000. BlackRock Inc. raised its position in shares of RadNet by 21.1% in the third quarter. BlackRock Inc. now owns 3,089,617 shares of the medical research company’s stock valued at $46,499,000 after buying an additional 537,422 shares during the last quarter. Finally, Royce & Associates LP raised its position in shares of RadNet by 104.8% in the fourth quarter. Royce & Associates LP now owns 272,423 shares of the medical research company’s stock valued at $2,771,000 after buying an additional 139,409 shares during the last quarter. Institutional investors and hedge funds own 63.80% of the company’s stock.
In related news, Director David L. Swartz sold 11,556 shares of the firm’s stock in a transaction dated Monday, March 18th. The shares were sold at an average price of $14.72, for a total transaction of $170,104.32. Following the completion of the sale, the director now directly owns 265,855 shares in the company, valued at $3,913,385.60. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Michael L. Md Sherman sold 20,000 shares of the firm’s stock in a transaction dated Wednesday, March 20th. The stock was sold at an average price of $13.89, for a total transaction of $277,800.00. Following the sale, the director now owns 279,720 shares of the company’s stock, valued at $3,885,310.80. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 46,556 shares of company stock valued at $672,754. 7.56% of the stock is owned by company insiders.
RDNT has been the subject of a number of recent research reports. BidaskClub cut shares of RadNet from a “hold” rating to a “sell” rating in a research report on Friday, December 21st. Zacks Investment Research upgraded shares of RadNet from a “sell” rating to a “hold” rating in a research report on Tuesday, March 5th. Raymond James cut shares of RadNet from a “strong-buy” rating to an “outperform” rating and raised their price objective for the stock from $16.00 to $17.50 in a research report on Friday, March 15th. They noted that the move was a valuation call. ValuEngine cut shares of RadNet from a “buy” rating to a “hold” rating in a research report on Tuesday, March 19th. Finally, TheStreet upgraded shares of RadNet from a “c” rating to a “b-” rating in a research report on Friday, March 15th. Three analysts have rated the stock with a hold rating and one has given a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $17.75.
RadNet stock opened at $12.71 on Wednesday. RadNet Inc. has a 12-month low of $9.97 and a 12-month high of $16.54. The stock has a market cap of $652.41 million, a P/E ratio of 19.26, a PEG ratio of 4.82 and a beta of 1.19. The company has a quick ratio of 0.87, a current ratio of 0.87 and a debt-to-equity ratio of 3.16.
RadNet (NASDAQ:RDNT) last released its quarterly earnings data on Thursday, March 14th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.18 by $0.41. RadNet had a net margin of 3.31% and a return on equity of 27.51%. The firm had revenue of $257.21 million during the quarter, compared to analysts’ expectations of $248.21 million. During the same period last year, the business earned ($0.15) earnings per share. RadNet’s revenue was up 9.2% compared to the same quarter last year. As a group, equities research analysts predict that RadNet Inc. will post 0.34 earnings per share for the current year.
RadNet, Inc, together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services.
Featured Story: What is Net Asset Value (NAV)?
Want to see what other hedge funds are holding RDNT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for RadNet Inc. (NASDAQ:RDNT).
Receive News & Ratings for RadNet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RadNet and related companies with MarketBeat.com's FREE daily email newsletter.